Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

93 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Risk factors for hepatocellular carcinoma at baseline and 1 year after initiation of nucleos(t)ide analog therapy for chronic hepatitis B.
Kaneko S, Kurosaki M, Mashiba T, Marusawa H, Kondo M, Kojima Y, Uchida Y, Fujii H, Akahane T, Yagisawa H, Kusakabe A, Kobashi H, Abe T, Yoshida H, Ogawa C, Furuta K, Tamaki N, Tsuji K, Matsushita T, Izumi N; Japanese Red Cross Liver Study Group. Kaneko S, et al. Among authors: mashiba t. J Med Virol. 2023 Jan;95(1):e28210. doi: 10.1002/jmv.28210. Epub 2022 Oct 20. J Med Virol. 2023. PMID: 36222204
Effects of antiviral therapy for hepatitis C following treatment of hepatocellular carcinoma: survey findings of the Japanese Red Cross Liver Study Group.
Joko K, Goto T, Watanabe H, Mitsuda A, Uchida Y, Hasebe C, Tsuruta S, Kimura H, Koike T, Akamatsu T, Mashiba T, Ochi H, Nakamura Y, Tsuchiya K, Kurosaki M, Izumi N. Joko K, et al. Among authors: mashiba t. Hepatol Res. 2016 Apr;46(4):251-8. doi: 10.1111/hepr.12515. Epub 2015 Mar 24. Hepatol Res. 2016. PMID: 25753220
Does interferon-free direct-acting antiviral therapy for hepatitis C after curative treatment for hepatocellular carcinoma lead to unexpected recurrences of HCC? A multicenter study by the Japanese Red Cross Hospital Liver Study Group.
Mashiba T, Joko K, Kurosaki M, Ochi H, Osaki Y, Kojima Y, Nakata R, Goto T, Takehiro A, Kimura H, Mitsuda A, Kawanami C, Uchida Y, Ogawa C, Kusakabe A, Narita R, Ide Y, Abe T, Tsuji K, Kitamura T, Okada K, Sohda T, Shigeno M, Satou T, Izumi N. Mashiba T, et al. PLoS One. 2018 Apr 16;13(4):e0194704. doi: 10.1371/journal.pone.0194704. eCollection 2018. PLoS One. 2018. PMID: 29659591 Free PMC article.
Real-world efficacy of elbasvir and grazoprevir for hepatitis C virus (genotype 1): A nationwide, multicenter study by the Japanese Red Cross Hospital Liver Study Group.
Mashiba T, Joko K, Kurosaki M, Ochi H, Hasebe C, Akahane T, Sohda T, Tsuji K, Mitsuda A, Kimura H, Narita R, Ogawa C, Furuta K, Shigeno M, Okushin H, Ito H, Kusakabe A, Satou T, Kawanami C, Nakata R, Kobashi H, Tamada T, Ide Y, Yagisawa H, Morita A, Matsushita T, Okada K, Izumi N. Mashiba T, et al. Hepatol Res. 2019 Oct;49(10):1114-1120. doi: 10.1111/hepr.13362. Epub 2019 Jun 14. Hepatol Res. 2019. PMID: 31077527 Free PMC article.
Efficacy of hepatitis C virus eradication after curative treatment for hepatocellular carcinoma in patients with advanced hepatocellular carcinoma and decreased hepatic functional reserve: A nationwide, multicentre study by the Japanese Red Cross Liver Study Group.
Mashiba T, Joko K, Kurosaki M, Ochi H, Marusawa H, Uchida Y, Fujii H, Kojima Y, Yoshida H, Goto T, Akahane T, Kondo M, Tsuji K, Mitsuda A, Hasebe C, Kusakabe A, Sohda T, Furuta K, Kobashi H, Ogawa C, Ide Y, Arai H, Okada K, Shigeno M, Nonogi R, Izumi N. Mashiba T, et al. J Viral Hepat. 2022 Jul;29(7):551-558. doi: 10.1111/jvh.13684. Epub 2022 May 18. J Viral Hepat. 2022. PMID: 35548866
Usefulness of neutrophil-to-lymphocyte ratio in predicting progression and survival outcomes after atezolizumab-bevacizumab treatment for hepatocellular carcinoma.
Ochi H, Kurosaki M, Joko K, Mashiba T, Tamaki N, Tsuchiya K, Marusawa H, Tada T, Nakamura S, Narita R, Uchida Y, Akahane T, Kondo M, Mori N, Takaki S, Tsuji K, Kusakabe A, Furuta K, Kobashi H, Arai H, Nonogi M, Tamada T, Hasebe C, Izumi N. Ochi H, et al. Among authors: mashiba t. Hepatol Res. 2023 Jan;53(1):61-71. doi: 10.1111/hepr.13836. Epub 2022 Oct 4. Hepatol Res. 2023. PMID: 36070216
Optimal threshold of alpha-fetoprotein response in patients with unresectable hepatocellular carcinoma treated with atezolizumab and bevacizumab.
Tamaki N, Tada T, Kurosaki M, Yasui Y, Ochi H, Mashiba T, Sakamoto A, Marusawa H, Narita R, Uchida Y, Akahane T, Kondo M, Mori N, Takaki S, Tsuji K, Kobashi H, Kusakabe A, Furuta K, Arai H, Nonogi M, Ogawa C, Sato T, Tamada T, Nakamura S, Hasebe C, Tsuchiya K, Izumi N. Tamaki N, et al. Among authors: mashiba t. Invest New Drugs. 2022 Dec;40(6):1290-1297. doi: 10.1007/s10637-022-01303-w. Epub 2022 Sep 24. Invest New Drugs. 2022. PMID: 36152108
Outcome of untreated low-level viremia versus antiviral therapy-induced or spontaneous undetectable HBV-DNA in compensated cirrhosis.
Huang DQ, Tamaki N, Lee HW, Park SY, Lee YR, Lee HW, Lim SG, Lim TS, Kurosaki M, Marusawa H, Mashiba T, Kondo M, Uchida Y, Kobashi H, Furuta K, Izumi N, Kim BK, Sinn DH. Huang DQ, et al. Among authors: mashiba t. Hepatology. 2023 May 1;77(5):1746-1756. doi: 10.1097/HEP.0000000000000037. Epub 2023 Jan 13. Hepatology. 2023. PMID: 36633913
Necessity for surveillance for hepatocellualr carcinoma in older patients with chronic hepatitis C who achieved sustained virological response.
Ishido S, Tamaki N, Kurosaki M, Mori N, Tsuji K, Hasebe C, Mashiba T, Ochi H, Yasui Y, Akahane T, Furuta K, Kobashi H, Fujii H, Ishii T, Marusawa H, Kondo M, Kusakabe A, Yoshida H, Uchida Y, Tada T, Nakamura S, Mitsuda A, Ogawa C, Arai H, Murohisa T, Uebayashi M, Izumi N. Ishido S, et al. Among authors: mashiba t. JGH Open. 2023 May 29;7(6):424-430. doi: 10.1002/jgh3.12914. eCollection 2023 Jun. JGH Open. 2023. PMID: 37359109 Free PMC article.
Effect of treatment periods on efficacy of glecaprevir and pibrentasvir in chronic hepatitis C: A nationwide, prospective, multicenter study.
Morita A, Tamaki N, Kobashi H, Mori N, Tsuji K, Takaki S, Hasebe C, Akahane T, Ochi H, Mashiba T, Urawa N, Fujii H, Mitsuda A, Kondo M, Ogawa C, Uchida Y, Narita R, Marusawa H, Kubotsu Y, Matsushita T, Shigeno M, Yoshida H, Tanaka K, Okamoto E, Kasai T, Ishii T, Okada K, Kurosaki M, Izumi N. Morita A, et al. Among authors: mashiba t. JGH Open. 2024 Apr 25;8(4):e13068. doi: 10.1002/jgh3.13068. eCollection 2024 Apr. JGH Open. 2024. PMID: 38681824 Free PMC article.
93 results